For more than 40 years ASHP has published the most trusted resource for injectable drug information. Our new ASHP (R) Injectable Drug Information now delivers the same high-quality content that you can expect from ASHP with even more of the information you need to make decisive patient care decisions. The 2023 edition of the industry's go-to guide is newly updated with the latest information, the full list of the AHFS (R) Pharmacologic-Therapeutic Classification (c) system, multiple new monographs, and nearly 200 new references for a total of over 24,000 total compatibility pairs. ASHP (R) Injectable Drug Information (TM) 2023 features more than 400 monographs, including: Brexanolone Cefiderocol sulfate tosylate Oritavancin Oliceridine fumarate Remdesivir Remimazolam besylate Sildenafil citrate

AHFS Drug Information (R) 2022 contains the most dependable drug information available-all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses. With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice. Updates in the new edition: The latest information on COVID-19 vaccines and COVID-19 monoclonal antibodies available under FDA Emergency Use Authorizations (EUAs), including clinical considerations from the US Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH). Information on patient selection and appropriate use of corticosteroids in the management of COVID-19 based on recent guidelines from NIH and the World Health Organization (WHO). Contemporary issues such as anticoagulant reversal strategies and use of direct oral anticoagulants versus warfarin for treatment of venous thromboembolism or atrial fibrillation. Current best practices such as reversal of neuromuscular blocking agents for prevention of postoperative residual neuromuscular blockade. Newly published information on breakthrough oncology drugs approved as part of the FDA's accelerated approval program. Expanded content on off-label uses, real-world data, and long-term clinical data. Updated information on pharmacogenomic considerations based on recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Addition of 51 new molecular entities (NMEs) or new therapeutic biological products approved since January 2021.